NLS Completes Open Label Extension Study in Narcolepsy

 

• Six-month Open Label Extension (OLE) study for patients that completed the POLARIS Phase 2 randomized, double-blind study has achieved its final patient visit

• 87% of patients who completed the POLARIS Phase 2 study requested to continue monotherapy treatment with Mazindol ER in the six-month OLE, rather than transition to other therapies

https://finance.yahoo.com/news/nls-pharmaceutics-announces-completion-open-133000459.html